Alcyone Therapeutics hopes to be a standout star and rising goddess in the central nervous system (CNS) treatment landscape. The Massachusetts biotech unveiled itself Wednesday with $23 million in ...

Expanded collaboration with Nationwide Children's Hospital adds new funding and a third therapeutic candidate (CLN-301) to Alcyone's diversified portfolio of precision CNS therapeutics and delivery ...

Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.

Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: ...

Biogen and Alcyone Therapeutics (Alcyone) have entered into a collaboration and licensing agreement to develop Alcyone’s ThecaFlex DRx System (ThecaFlex) to improve patient experience and access to ...

The PIERRE pivotal study (https://clinicaltrials.gov/ct2/show/NCT05866419) will enroll up to 90 patients and will be conducted in two stages. The first stage is ...

LOWELL — Alcyone Lifesciences Inc., a biotech startup that moved its headquarters to the Boott Mill last summer, said it has entered into an “exclusive clinical collaboration” with Houston-based ...

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in ...